Clinical trial · Interventional
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
NCT06866977CI-TRIAL-00086961not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, single-arm, open label investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Oncolytic virus VRT106 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VRT106 combination with chemotherapy
- description
- VRT106 combination with chemotherapy
- interventionNames
- Drug: Oncolytic virus VRT106
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Safety and tolerability
- timeFrame
- About 3 years
- description
- Incidence rate of TRAE
Secondary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- About 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures. * Males and females≥18 years of age, inclusive, at the Screening Visit. * Have unresectable pancreatic cancer as determined by imaging or surgical exploration and locally advanced or metastatic pancreatic ductal adenocarcinoma (including adenosquamous carcinoma) as confirmed by histology or cytology. * No prior systemic therapy for unresectable locally advanced and metastatic pancreatic cancer. * Have at least one measurable lesion according to RECIST v1.1 criteria. * An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. * Expected survival time of≥3 months. * No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions. Exclusion Criteria: * Have suffered from other malignant tumors in the past 5 years, except for cured basal cell skin cancer, non-melanoma skin cancer, and cervical cancer in situ. * Previous treatment with other oncolytic viruses. * Immunocompromised patients. * Known alcohol or drug dependency. * Women who are pregnant or breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.